Degradation and metabolism of mometasone furoate in humans: Influence of reversible, sequential metabolism, and ionic strength

被引：2
作者：
Davies, NM [1 ]
机构：
[1] Washington State Univ, Dept Pharmaceut Sci, Coll Pharm, Pullman, WA 99163 USA
来源：
JOURNAL OF PHARMACEUTICAL SCIENCES | 2004年 / 93卷 / 12期
关键词：
D O I：
10.1002/jps.20189
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：2877 / 2880
页数：4
相关论文
共 21 条
  • [1] ANDERSSON P, 1984, J PHARM PHARMACOL, V36, P763, DOI 10.1111/j.2042-7158.1984.tb04868.x
  • [2] Unusual hydroxy-γ-sultone byproducts of steroid 21-methanesulfonylation.: An efficient synthesis of mometasone 17-furoate (Sch 32088)
    Draper, RW
    Hu, B
    McPhail, A
    Puar, MS
    Vater, EJ
    Weber, L
    [J]. TETRAHEDRON, 1999, 55 (11) : 3355 - 3364
  • [3] An unusual dienone-phenol rearrangement product formed during the synthesis of mometasone furoate (Sch 32088)
    Draper, RW
    Puar, MS
    Vater, EJ
    McPhail, AT
    [J]. STEROIDS, 1998, 63 (03) : 135 - 140
  • [4] Foe K, 2000, J PHARM SCI-US, V89, P1143, DOI 10.1002/1520-6017(200009)89:9<1143::AID-JPS6>3.0.CO
  • [5] 2-C
  • [6] BINDING AFFINITIES OF MOMETASONE FUROATE AND RELATED-COMPOUNDS INCLUDING ITS METABOLITES FOR THE GLUCOCORTICOID RECEPTOR OF RAT SKIN TISSUE
    ISOGAI, M
    SHIMIZU, H
    ESUMI, Y
    TERASAWA, T
    OKADA, T
    SUGENO, K
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1993, 44 (02) : 141 - 145
  • [7] Sahasranaman S, 2004, PHARMAZIE, V59, P367
  • [8] Mometasone furoate degradation and metabolism in human biological fluids and tissues
    Teng, XW
    Cutler, DJ
    Davies, NM
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2003, 24 (08) : 321 - 333
  • [9] Kinetics of metabolism and degradation of mometasone furoate in rat biological fluids and tissues
    Teng, XW
    Cutler, DJ
    Davies, NM
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (05) : 617 - 630
  • [10] Degradation kinetics of mometasone furoate in aqueous systems
    Teng, XW
    Cutler, DC
    Davies, NM
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 259 (1-2) : 129 - 141
123